Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers
Despite surgical and therapeutic advances, glioblastoma multiforme (GBM) is among the most fatal primary brain tumor that is aggressive in nature. Patients with GBM have a median lifespan of just 15 months when treated with the current standard of therapy, which includes surgical resection and conco...
Saved in:
Main Authors: | Ruijia Liang (Author), Cheng Wu (Author), Shiming Liu (Author), Wenyan Zhao (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex
by: Maxim A.X. Tollenaere, et al.
Published: (2023) -
IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma
by: Julian S. Rechberger, et al.
Published: (2022) -
IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients
by: Maryam Karamikheirabad, et al.
Published: (2024) -
Expression of IL4Rα and IL13Rα1 are associated with poor prognosis of soft-tissue sarcoma of the extremities, superficial trunk, and retroperitoneum
by: Kyoung Min Kim, et al.
Published: (2021) -
Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model
by: Parul Gupta, et al.
Published: (2021)